Questions for the TSE Advisory Committee

October 26, 2001

TOPIC 3

 

  1. What is the public health risk to consumers that would warrant consideration of prohibiting the sale of bovine brain and products containing brain for human use?
  2. Is there a consistent and appreciable difference in infectivity of various sections/areas of bovine brain? If so, what are the differences in relative degrees of infectivity of these areas?
  3. Are there other bovine neurological tissues that, if used in consumer products (such as foods, dietary supplements, cosmetics, and certain non-application drugs), could also pose a significant health hazard? If so, what are the differences in relative degrees of infectivity of these tissues?
  4. What physical, chemical, or biological factors of tissues and/or processes should FDA consider in reviewing procedures that may have the ability to reduce infectivity of bovine neurological tissues and products containing bovine neurological tissues?
  5. What tests are available to ascertain changes in infectivity in products containing bovine neurological tissues as a result of processing?
  6. What level of reduction in infectivity is necessary to consider products containing bovine neurological tissues non-infective or "safe" for human use?